Holly Shill, MD
Neurology · Phoenix, AZNPI 1922034636
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.0%. Reporting peaked in 2019 at $30,034 and has fallen 83.6% since, to $4,940 in 2025. Among neurology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 99 payments — averaging $557.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$12K
- Jazz Pharmaceuticals Inc.$10K
- Biogen$9K
- MDD US Operations, LLC$7K
- Amneal Pharmaceuticals LLC$5K
- Kyowa Kirin, Inc.$2K
- plus $10K from 15 others
Across 181 payments — averaging $4601.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche TCRC, Inc.$198K
- Biogen$173K
- Lundbeck LLC$137K
- Amneal Pharmaceuticals LLC$127K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$91K
- UCB SA$62K
- plus $46K from 3 others
What the payments were for
- Consulting fees$32,46659%
- Speaking & faculty fees$13,96325%
- Travel & lodging$4,9309%
- Food & beverage$3,6897%
- Education$1650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 13 | $12,164 |
| Jazz Pharmaceuticals Inc. | 18 | $9,580 |
| Biogen | 6 | $9,342 |
| MDD US Operations, LLC | 22 | $7,496 |
| Amneal Pharmaceuticals LLC | 1 | $4,725 |
| Kyowa Kirin, Inc. | 3 | $2,322 |
| Acorda Therapeutics, Inc | 1 | $2,200 |
| Tanabe Pharma America, Inc. | 2 | $1,800 |
| AbbVie(2 entities) | 7 | $1,366 |
| Neurocrine Biosciences, Inc. | 3 | $1,241 |
| Sumitomo Pharma America, Inc. | 1 | $938 |
| Boston Scientific | 4 | $654 |
| Medtronic(2 entities) | 5 | $341 |
| Cala Health, Inc. | 1 | $300 |
| Supernus Pharmaceuticals, Inc. | 1 | $290 |
| Abbott | 6 | $255 |
| Teva Pharmaceuticals USA, Inc. | 1 | $103 |
| Merz Pharmaceuticals, LLC | 1 | $35 |
| Avion Pharmaceuticals | 1 | $26 |
| Hoffmann-la Roche Limited | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,213 in reported general payments places this provider in the 90th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 117 | $232,038 |
| GocovriAmantadine Hcl | 61 | $169,432 |
| NuplazidPimavanserin Tartrate | 24 | $130,053 |
| ApokynApomorphine Hcl | 13 | $127,913 |
| IngrezzaValbenazine Tosylate | 17 | $127,270 |
| NeuproRotigotine | 37 | $61,990 |
| NourianzIstradefylline | 16 | $41,308 |
| Rasagiline Mesylate | 180 | $36,176 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 776 | $28,663 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 252 | $20,339 |
| AmantadineAmantadine Hcl | 283 | $12,494 |
| Droxidopa | 16 | $9,099 |
| Ropinirole ErRopinirole Hcl | 62 | $8,529 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 142 | $4,291 |
| Selegiline Hcl | 21 | $3,751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $4,725 | $232,038117 claims |
| MDD US Operations, LLCGocovri | $7,496 | $169,43261 claims |
| Acadia Pharmaceuticals IncNuplazid | $12,164 | $130,05324 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,241 | $127,27017 claims |
| Kyowa Kirin, Inc.Nourianz | $2,322 | $41,30816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 neurology providers in Arizona.
Other neurology in Phoenix
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
- Lori TravisPhoenix$406K
- Jeffrey GittPhoenix$275K
- Todd SchwedtPhoenix$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.